Sterling Capital Management’s DiaMedica Therapeutics DMAC Stock Holding History

Sterling Capital Management’s Portfolio DMAC Stock Details DMAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$9.9K	Buy	1,202 +1,073	+832%	+$7.5K	﹤0.01%	2531
2026 Q2	$908	Sell	129 -77	-37%	-$473	﹤0.01%	3149
2026 Q1	$1.4K	Hold	206	–	–	﹤0.01%	3046
2025 Q4	$1.64K	Buy	206 +129	+168%	+$965	﹤0.01%	3089
2025 Q3	$529	Buy	77 +13	+20%	+$71	﹤0.01%	3151
2025 Q2	$250	Buy	+64	New	+$250	﹤0.01%	3221

Other funds holding DMAC

Members Wealth Media, Pennsylvania $200M AUM 9.84% 1-Year Est. Return

Blue Trust Inc Alpharetta, Georgia $9.5B AUM 13.02% 1-Year Est. Return

MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

GK Wealth Management Reno, Nevada $178M AUM 41.48% 1-Year Est. Return

TD Waterhouse Canada Toronto, Ontario, Canada $38.4B AUM 30.28% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

Root Financial Partners Encinitas, California $2.98B AUM 13.9% 1-Year Est. Return

Sterling Capital Management's DMAC Position: Q3 2026 in Review

Sterling Capital Management increased its DiaMedica Therapeutics (DMAC) stake by 832% in Q3 2026, buying an estimated $7.5K and bringing the position to 1,202 shares worth $9.9K. The position accounts for ﹤0.01% of the portfolio, ranked #2531.

Sterling Capital Management first reported a position in DMAC in Q2 2025 and has held it in 6 quarters since. 10 funds tracked by Wall St. Rank hold DMAC as of Q3 2026.

Sterling Capital Management held 1,202 shares of DiaMedica Therapeutics worth $9.9K as of Q3 2026.
Sterling Capital Management bought 1,073 DiaMedica Therapeutics shares in Q3 2026, an estimated $7.5K.
DiaMedica Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q3 2026, its #2531 holding.
Sterling Capital Management first reported a position in DiaMedica Therapeutics in Q2 2025 and has held it in 6 quarters since.
10 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q3 2026.

Based on Sterling Capital Management's 13F filing for Q3 2026, filed 22 Oct 2026.